In NB, our understanding of resistance to ALK inhibition is limited to pre-clinical studies of short treatment duration and have therefore focused primarily on the de novo resistance of ALK F1174L to crizotinib and ceritinib [60,93,94,97,98]. The gene discussed is ALK; the disease is neuroblastoma.